Table 1 Association between transcriptional subtypes and clinical benefit to immune checkpoint blockade across relapsed SCLC cohorts.

From: Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer

Transcriptional subtype

Clinical benefit (# of tumors)

No clinical benefit (# of tumors)

p valuea

ASCL1

2

22

0.11

NEUROD1

3

9

0.40

POU2F3

1

0

0.17

YAP1

2

8

0.78

  1. aStatistical significance calculated using the two-tailed chi-squared test.
Back to article page